RT Journal Article
SR Electronic
T1 Population Pharmacokinetic Analysis of Dexmedetomidine in Children using Real World Data from Electronic Health Records and Remnant Specimens
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.03.21256553
DO 10.1101/2021.05.03.21256553
A1 James, Nathan T.
A1 Breeyear, Joseph H.
A1 Caprioli, Richard
A1 Edwards, Todd
A1 Hachey, Brian
A1 Kannankeril, Prince J.
A1 Keaton, Jacob M.
A1 Marshall, Matthew D.
A1 Van Driest, Sara L.
A1 Choi, Leena
YR 2021
UL http://medrxiv.org/content/early/2021/11/03/2021.05.03.21256553.abstract
AB Aim Our objectives were to perform a population pharmacokinetic analysis of dexmedetomidine in children using remnant specimens and data from electronic health records (EHRs) and explore the impact of patient’s characteristics and pharmacogenetics on dexmedetomidine clearance.Methods Dexmedetomidine dosing and patient data were gathered from EHRs and combined with opportunistically sampled remnant specimens. Population pharmacokinetic models were developed using nonlinear mixed-effects modeling. The first stage developed a model without genotype variables; the second stage added pharmacogenetic effects.Results Our final study population included 354 post-cardiac surgery patients age 0 to 22 years (median 16 months). The final two-compartment model included allometric weight scaling and age maturation. Population parameter estimates and 95% confidence intervals were 27.3 L/hr (24.0 – 31.1 L/hr) for total clearance (CL), 161 L (139 – 187 L) for central compartment volume of distribution (V1), 26.0 L/hr (22.5 – 30.0 L/hr) for intercompartmental clearance (Q), and 7903 L (5617 – 11119 L) for peripheral compartment volume of distribution (V2). The estimate for postmenstrual age when 50% of adult clearance is achieved was 42.0 weeks (41.5 – 42.5 weeks) and the Hill coefficient estimate was 7.04 (6.99 – 7.08). Genotype was not statistically or clinically significant.Conclusion Our study demonstrates the use of real-world EHR data and remnant specimens to perform a population PK analysis and investigate covariate effects in a large pediatric population. Weight and age were important predictors of clearance. We did not find evidence for pharmacogenetic effects of UGT1A4 or UGT2B10 genotype or CYP2A6 risk score.What is already known about this subject∘ Previous dexmedetomidine pharmacokinetic (PK) studies in pediatric populations have limited sample size.∘ Smaller studies present a challenge for identifying covariates that may impact individual PK profiles.What this study adds∘ We performed a dexmedetomidine population PK study with a large pediatric cohort using data obtained from electronic health records and remnant plasma specimens to enable increased sample size.∘ xsDifferences in PK due to UGT1A4 or UGT2B10 variants or CYP2A6 risk score are not clinically impactful for this population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLC, NTJ, and SLV are supported by NIH/NIGMS (R01 GM124109). This work was supported in part by NIH/NIGMS (MS), NICHD R01 HD084461 and NIH National Center for Advancing Translational Sciences UL1 TR000445 (Vanderbilt CTSA).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Vanderbilt University Medical Center Institutional Review Board; IRB #070106I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not publicly available.